Drug Profile
Research programme: herpes simplex virus vaccine - AlphaVax
Alternative Names: HSV alphavaccine - AlphaVax; HSV vaccine - AlphaVaxLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator AlphaVax
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Parenteral)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections(Prevention) in USA (Parenteral)
- 24 Jul 2020 HSV vaccine is still in preclinical development for Herpes-simplex-virus-infections in USA (AlphaVax pipeline, July 2020)